PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SignaBlok, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Awarded NCI Grant to Test New Approach to Lung Cancer Treatment - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer - SignaBlok.com
SignaBlok Awarded NCI Grant to Test New Approach to Lung Cancer Treatment

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2012/10/01 - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer - SignaBlok.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), has awarded SignaBlok, Inc., a Massachusetts-based emerging biopharmaceutical company, a $221,738 Small Business Innovation Research (SBIR) grant to in vivo test a new approach to treatment of non-small cell lung cancer (NSCLC).

Cancer-related inflammation promotes NSCLC progression and metastasis. SignaBlok’s innovative approach targets a specific receptor called TREM-1 that serves as an inflammation amplifier and is expressed on tumor-associated inflammatory cells, macrophages.

The grant,“Development of novel targeted agents in lung cancer”, combines two novel SignaBlok’s proprietary technologies: 1) ligand-independent inhibition of cell receptors, known as the SCHOOL technology, and 2) nanotechnology for macrophage-targeted drug delivery.

The NCI funds will support formulation development and in vivo proof-of-concept studies to evaluate the anticancer efficacy of TREM-1-specific SCHOOL peptides in either the free or nanoparticulate form. The most promising formulations will be selected for Investigational New Drug (IND)-enabling toxicology studies and further clinical development. This could ultimately lead to first-in-class therapies for cancer.

“This award from the NCI/NIH reinforces the promise of our SCHOOL technology and innovative drug delivery nanosystems,” said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. “We have recently succeeded in the animal proof-of-concept testing of these technologies in sepsis. With the NCI funding, we hope to establish in vivo proof of concept for NSCLC. This will set the stage for the development of new therapies for not only NSCLC but also other inflammation-associated cancers such as pancreatic and colon cancers, thereby leading to a higher survival rate of the patients.”

About non-small cell lung cancer: NSCLC is the most common type of lung cancer. It kills more patients than breast, colon, and prostate cancer combined, and the 5-year survival rate is as low as 15%. Current treatments of NSCLC all have multiple shortcomings including only a modest increase in survival and significant toxicity to the patient. The limitations in efficacy and safety associated with available treatments for NSCLC highlight the need for new treatments.

About SignaBlok

SignaBlok (signablok.com) is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Awarded NCI Grant to Test New Approach to Lung Cancer Treatment

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)